Drug Discovery News: E. coli may hold the key to manufacturing hard-to-make drugs | Absci Media Highlights Archives - Absci

Our founder and CEO, Sean McClain, spoke with Drug Discovery News about how Absci combines engineered E. coli with artificial intelligence to design effective, quality protein- and antibody-based drug candidates. Read more.

On Thursday, July 22, 2021, Absci debuted on Wall Street with an IPO, raising about $200 million in the name of further developing our AI-powered Integrated Drug Creation Platform™ to identify biologics and help speed the development of new treatments. 

Our public debut generated buzz among both the business and life sciences communities. For more information, check out the list of the top ten news articles covering the IPO:

  1. Barron’s: Absci Stock Pops 35% in its IPO, While Couchbase Rises 27%
  2. TechCrunch: Shares of protein discovery platform Absci pop in market debut
  3. FOX Business: Cavuto Coast to Coast
  4. Seeking Alpha: IPO Day With Absci CEO Sean McClain – The Google Of Synthetic Biology (Video)
  5. BioPharma Reporter: Biotech Absci sees shares soar in IPO debut
  6. The Oregonian: Absci’s IPO values Vancouver biotech startup at $1.4 billion
  7. GeekWire: How Sean McClain founded Absci at just 22 — and now leads a newly public biotech worth nearly $2B
  8. Axios: Fusing synthetic biology and AI for faster drug discovery
  9. Portland Business Journal: ​​Absci shares surge after company’s Nasdaq debut
  10. The Columbian: Vancouver-based Absci valued at nearly $2 billion in IPO trading

Sean McClain, CEO and founder of Absci, spoke with TechCrunch about the company’s recent accomplishments and journey to IPO. Read more.

Absci CEO and Founder Sean McClain explains his company’s outlook and his experience going public via an IPO. Read more.

Totient, a biotech company harnessing human immune responses to identify novel antibodies and their therapeutic targets, has been acquired by Absci. Read more.

Absci CEO and Founder Sean McClain spoke with GEN about how its Escherichia coli platforms are engineered to defy known cell line limitations and enable high-titer scale-up of challenging biologics. Read more.

Endpoints News names Sean McClain, CEO and founder of Absci, to its 20 Under Forty in Biopharma list. Read more.

AbSci has secured $125 million in financing that it plans to use to further develop its artificial intelligence platform for creating synthetic biology drugs. Read more.

AbSci raised an additional $65 million to help grow its synthetic biology platform for discovering and manufacturing complex biological molecules such as antibodies and insulin. Read more.